Retrospective Cohort Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. May 24, 2019; 10(5): 201-212
Published online May 24, 2019. doi: 10.5306/wjco.v10.i5.201
Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
Trishala Meghal, Vishangi Dave, Horace Tang, Vivek Kumar, Yiqing Xu
Trishala Meghal, Vishangi Dave, Yiqing Xu, Department of Medicine, Division of Hematology/Oncology, Maimonides Medical Center, Brooklyn, NY 11219, United States
Horace Tang, Queens Hospital Center, Jamaica, NY 11418, United States
Vivek Kumar, Department of General Internal Medicine, Brigham and Women’s Hospital, Boston, MA 02115, United States
Author contributions: Meghal T, Dave V, Tang H and Xu Y contributed to the data collection and data analysis; Kumar V contributed to the statistical analysis; Meghal T, Kumar V and Xu Y wrote the manuscript; and all the authors approved the manuscript.
Institutional review board statement: IRB approved study on 11/2/2015, and the study was reviewed and approved by IRB annually.
Informed consent statement: No consent required, it is a retrospective study.
Conflict-of-interest statement: No one has conflict of interest in relevance to this study.
Data sharing statement: De-identified data on the clinical characteristics, treatment, toxicity and outcomes can be shared with the editor upon request, and upon IRB approval.
STROBE statement: The study was conducted and the manuscript was prepared with the guidance of the STROBE statement.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yiqing Xu, MD, PhD, Associate Professor, SUNY Downstate College of Medicine, Division of Hematology and Oncology, Department of Internal Medicine, Maimonides Medical Center, 6300 8th Avenue, Brooklyn, NY 11220, United States. yxu@maimonidesmed.org
Telephone: +1-718-7652600 Fax: +1-718-7652630
Received: January 3, 2019
Peer-review started: January 4, 2019
First decision: January 26, 2019
Revised: March 12, 2019
Accepted: March 26, 2019
Article in press: March 27, 2019
Published online: May 24, 2019
Processing time: 141 Days and 8.5 Hours
Core Tip

Core tip: Intraperitoneal chemotherapy has shown survival benefits in the adjuvant setting among the patients with advanced stage ovarian carcinoma undergoing debunking surgery. However, this intraperitoneal route could not be widely adopted due to a number of issues including patients choice and its cumbersome nature. The present study explores its feasibility in a community cancer setting. We have retrospectively analyzed the rates of toxicities and outcome of the patients who received this therapy in our cancer center. We conclude that intraperitoneal chemotherapy can be safely administered in the community cancer setting and improves the overall and progression free survival.